SPARCL1 and breast cancer: The above findings suggest that SPARCL1 expression was downregulated both in BC and liver metastasis, and its low expression correlates with younger age, high TNM stages, and HR negative status of patients, implying that SPARCL1 may play a tumor suppressive role in BC patients.